CSIMarket
 
Iradimed Corporation  (IRMD)
Other Ticker:  
 
 
Price: $44.2700 $0.73 1.677%
Day's High: $44.3 Week Perf: 2.45 %
Day's Low: $ 43.24 30 Day Perf: -3.23 %
Volume (M): 86 52 Wk High: $ 51.04
Volume (M$): $ 3,807 52 Wk Avg: $44.23
Open: $43.24 52 Wk Low: $36.12



 Market Capitalization (Millions $) 564
 Shares Outstanding (Millions) 13
 Employees -
 Revenues (TTM) (Millions $) 63
 Net Income (TTM) (Millions $) 16
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 8

Iradimed Corporation
Iradimed Corporation is a medical technology company that specializes in the development and manufacturing of MRI-compatible intravenous (IV) infusion pumps and other related products. The company was founded in 1992 and is based in Winter Springs, Florida.

Iradimed's flagship product is the MRidium MRI-compatible IV infusion pump system, which is designed to safely deliver medication and fluids to patients undergoing magnetic resonance imaging (MRI) procedures. The MRidium pump system is unique in that it is specifically engineered to be used in the MRI environment, where traditional infusion pumps are not safe or suitable due to the strong magnetic fields and radio frequency interference.

The company also offers a range of associated products and accessories, including IV sets, administration sets, and tubing, all designed for use in the MRI environment. These products are primarily sold to hospitals and other healthcare facilities.

Iradimed Corporation has established a strong presence in the medical technology industry, with its products being used in leading hospitals worldwide. Their MRI-compatible IV infusion pump system is highly regarded for its safety, durability, and ease of use. The company continues to innovate and develop new products to meet the evolving needs of the healthcare industry.


   Company Address: 1025 Willa Springs Drive Winter Springs 32708 FL
   Company Phone Number: 677-8022   Stock Exchange / Ticker: NASDAQ IRMD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Iradimed Corporation

Iradimed Corporation Achieves Remarkable Double-Digit EPS Growth of 48.15% in the Latest Fiscal Period

Bearish Outlook for Iradimed Corporation
Iradimed Corporation recently announced strong results for the third quarter of 2023, with a 23.102% increase in revenue to $16.50 million and a 48.15% rise in profit per share to $0.40. The Medical Equipment & Supplies company's business outperformed its peers in the sector, with an average business rise of only 2.23% for the two third entities in the same industry. However, upon closer examination, there are several concerning factors that indicate a potential decline in the company's prospects.
While earnings grew by 21.21% from $0.33 per share and revenue surged by 2.32% from $16.13 million compared to the previous year, the net earnings of $5.067 million represent a significant increase of 47.86% from the net earnings of $3.427 million reported during the same period a year ago. Although this seems positive at first glance, it is essential to consider the overall trend. The growth in earnings and revenue is significantly lower compared to the level of growth experienced in the preceding year.

Iradimed Corporation

Iradimed Corporation Shatters Industry Norms: Revenue and Earnings Skyrocket in Recent Fiscal Period



Iradimed Corporation, a leading Medical Equipment & Supplies company, recently announced its financial results for the most recent fiscal period. The company experienced significant growth in revenue and earnings per share, outperforming industry peers during the second quarter of 2023. This article will delve deeper into the financial facts and provide an analysis of Iradimed Corporation's performance within the context of the broader market.
Financial Highlights:
1. Revenue Growth: Iradimed Corporation witnessed a remarkable 26.796% increase in revenue, reaching $16.13 million for the most recent fiscal period. This growth rate far exceeded the average business growth of 1.52% reported by its Medical Equipment & Supplies industry contemporaries.

Iradimed Corporation

Iradimed Corporation Reports Impressive Financial Results in Q1 2023, with Revenue Soaring by 25.704% and Earnings Surging by 35% Year on Year

Iradimed Corporation, a medical device company, has announced strong financial results in the first quarter of 2023 with revenue rising by 25.704% to $15.48 million, and profit per share jumping by 35% to $0.27 per share year on year. The net income of $3.406 million in the most recent fiscal period increased by 36.97% from net earnings of $2.487 million reported in the most recent fiscal period a year ago.
The company's financial performance in the first quarter of 2023 was impressive as compared to the prior period net profit per share had decreased by -7.01% from $0.29 per share, and revenue increased by 4.114% from $14.86 million. Iradimed Corporation also emphasized its improving profit margins, where the net margin rose to 22.01% in the most recent fiscal period, and operating margin edged up to 25.89%. Operating earnings, on the other hand, improved by just 30.32% to $4.007246 million.
Iradimed Corporation is a dynamic company that specializes in the development, manufacture, and marketing of innovative MRI-compatible medical devices. The company's primary focus is on the development and delivery of neonatal and pediatric products as well as adult products that are compact, lightweight, and easy to operate. The products are designed to be used in the ICU, emergency department, and MRI suite.






 

Iradimed's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com